ROLE OF PLATELETS IN PROGRESSIVE GLOMERULAR-DISEASES

被引:64
作者
ZOJA, C [1 ]
REMUZZI, G [1 ]
机构
[1] MARIO NEGRI INST PHARMACOL RES,NEGRI BERGAMO LABS,I-24125 BERGAMO,ITALY
关键词
PLATELETS; PROGRESSIVE GLOMERULAR DISEASES;
D O I
10.1007/BF00866739
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
There is increasing evidence that platelets are involved in the pathogenesis of glomerulonephritis. Intraglomerular platelets or their degradation products are observed in biopsies from patients with lupus nephritis, mesangioproliferative, membranous or IgA nephropathy. Moreover shortened platelet survival in patients with various glomerular diseases has also been described. In models of experimental glomerulonephritis, platelets may participate in glomerular injury, together with other mediators, by complex mechanisms, As extensively documented, platelets release within the glomerulus vasoactive, chemotactic and mitogenic substances that interact with a number of soluble mediators generated by renal resident or inflammatory cells and contribute to amplify glomerular injury. Thus platelet-activating factor and other platelet secretory products, polycationic macromolecules, platelet factor 4 and beta-thromboglobulin, alter glomerular permeability to proteins and enhance immune-mediated glomerular injury, Platelet-derived factors, like platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF beta) mediate renal disease progression in experimental and human glomerulonephritis via their chemotactic activity for infiltrating leucocytes and their effect of promoting extracellular matrix synthesis by resident renal cells. In these settings increased renal expression of PDGF and TGF beta has correlated with clinical features. Specific PDGF and TGF beta inhibitors ameliorated experimental glomerular disease. A wide variety of therapies to inhibit platelet function have been employed over the years, however the results of clinical studies are controversial and do not allow conclusions to be drawn about the efficacy of anti-platelet agents in progressive renal disease. Identification of specific platelet inhibitors or interventions specific for platelet secretory products and their target cells will be crucial for understanding the exact role of platelets and their products in glomerular disease.
引用
收藏
页码:495 / 502
页数:8
相关论文
共 86 条
[1]  
Ardlie N.G., Mechanism of platelet aggregation and release. their possible role in vascular injury, Glomerulonephritis. Morphology, natural history, and treatment, (1972)
[2]  
Cochrane C.G., Mechanisms involved in the deposition of immune complexes in tissues, J Exp Med, 134, pp. 75-89, (1971)
[3]  
Clark W.F., Friesen M., Linton A.L., Lindsay R.M., The platelets as mediator of tissue damage in immune-complex glomerulonephritis, Clin Nephrol, 6, pp. 287-289, (1976)
[4]  
Parbtani A., Cameron J.S., Platelet involvement in glomerulonephritis, Hemostasis, prostaglandins and renal disease, (1980)
[5]  
Duffy J.L., Cinque T., Grishman E., Churg J., Intraglomerular fibrin, platelet aggregation and subendothelial deposits in lipoid nephrosis, J Clin Invest, 49, pp. 251-258, (1970)
[6]  
Kincaid-Smith P., Coagulation and renal disease, Kidney Int, 2, pp. 183-189, (1972)
[7]  
Nakajima M., Hewitson T.D., Mathews D.C., Kincaid-Smith P., Platelet-derived growth factor mesangial deposits in mesangial IgA glomerulonephritis, Nephrol Dial Transplant, 6, pp. 11-16, (1991)
[8]  
Mustard J.F., Packham M.A., The role of blood and platelets in atherosclerosis and the complications of atherosclerosis, Thromb Diath Haemorrh, 33, pp. 444-456, (1975)
[9]  
Vermylen J., Carreras L.O., The process of hemostasis, Cardiovascular pharmacology of the prostaglandins, (1982)
[10]  
Wu X., Pippin J., Lefkowith J.B., Platelets and neutrophils are critical to the enhanced glomerular arachidonate metabolism in acute nephrotoxic nephritis in rats, J Clin Invest, 91, pp. 766-773, (1993)